 Carcinoma, Renal Cell
"Carcinoma, Renal Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.
| Descriptor ID |
D002292
|
| MeSH Number(s) |
C04.557.470.200.025.390 C04.588.945.947.535.160 C12.758.820.750.160 C12.777.419.473.160 C13.351.937.820.535.160 C13.351.968.419.473.160
|
| Concept/Terms |
Carcinoma, Renal Cell- Carcinoma, Renal Cell
- Carcinomas, Renal Cell
- Renal Cell Carcinomas
- Renal Cell Carcinoma
- Renal Cell Cancer
- Cancer, Renal Cell
- Cancers, Renal Cell
- Renal Cell Cancers
- Adenocarcinoma, Renal Cell
- Adenocarcinomas, Renal Cell
- Renal Cell Adenocarcinoma
- Renal Cell Adenocarcinomas
- Nephroid Carcinoma
- Carcinoma, Nephroid
- Carcinomas, Nephroid
- Nephroid Carcinomas
Clear Cell Renal Cell Carcinoma- Clear Cell Renal Cell Carcinoma
- Hypernephroma
- Hypernephromas
- Grawitz Tumor
- Tumor, Grawitz
- Carcinoma, Hypernephroid
- Carcinomas, Hypernephroid
- Hypernephroid Carcinoma
- Hypernephroid Carcinomas
- Clear Cell Renal Carcinoma
Collecting Duct Carcinoma (Kidney)- Collecting Duct Carcinoma (Kidney)
- Carcinoma, Collecting Duct (Kidney)
- Carcinomas, Collecting Duct (Kidney)
- Collecting Duct Carcinomas (Kidney)
- Duct Carcinoma, Collecting (Kidney)
- Duct Carcinomas, Collecting (Kidney)
- Collecting Duct Carcinoma of the Kidney
- Renal Collecting Duct Carcinoma
- Collecting Duct Carcinoma
- Carcinoma, Collecting Duct
- Carcinomas, Collecting Duct
- Collecting Duct Carcinomas
- Duct Carcinoma, Collecting
- Duct Carcinomas, Collecting
|
Below are MeSH descriptors whose meaning is more general than "Carcinoma, Renal Cell".
Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Renal Cell".
This graph shows the total number of publications written about "Carcinoma, Renal Cell" by people in this website by year, and whether "Carcinoma, Renal Cell" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1985 | 0 | 1 | 1 | | 1986 | 2 | 1 | 3 | | 1989 | 1 | 0 | 1 | | 1990 | 1 | 0 | 1 | | 1991 | 1 | 0 | 1 | | 1992 | 3 | 0 | 3 | | 1993 | 1 | 0 | 1 | | 1994 | 3 | 0 | 3 | | 1995 | 2 | 0 | 2 | | 1996 | 1 | 2 | 3 | | 1997 | 1 | 0 | 1 | | 1998 | 5 | 0 | 5 | | 1999 | 3 | 0 | 3 | | 2000 | 8 | 0 | 8 | | 2001 | 3 | 3 | 6 | | 2002 | 8 | 0 | 8 | | 2003 | 6 | 1 | 7 | | 2004 | 13 | 1 | 14 | | 2005 | 10 | 3 | 13 | | 2006 | 18 | 2 | 20 | | 2007 | 11 | 1 | 12 | | 2008 | 17 | 0 | 17 | | 2009 | 10 | 0 | 10 | | 2010 | 12 | 2 | 14 | | 2011 | 6 | 1 | 7 | | 2012 | 3 | 1 | 4 | | 2013 | 9 | 1 | 10 | | 2014 | 13 | 2 | 15 | | 2015 | 9 | 1 | 10 | | 2016 | 16 | 0 | 16 | | 2017 | 7 | 1 | 8 | | 2018 | 10 | 1 | 11 | | 2019 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Carcinoma, Renal Cell" by people in Profiles.
-
Rini BI, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, Bracarda S, Stadler WM, Donskov F, Lee JL, Hawkins R, Ravaud A, Alekseev B, Staehler M, Uemura M, De Giorgi U, Mellado B, Porta C, Melichar B, Gurney H, Bedke J, Choueiri TK, Parnis F, Khaznadar T, Thobhani A, Li S, Piault-Louis E, Frantz G, Huseni M, Schiff C, Green MC, Motzer RJ. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet. 2019 06 15; 393(10189):2404-2415.
-
Patel HD, Puligandla M, Shuch BM, Leibovich BC, Kapoor A, Master VA, Drake CG, Heng DY, Lara PN, Choueiri TK, Maskens D, Singer EA, Eggener SE, Svatek RS, Stadler WM, Cole S, Signoretti S, Gupta RT, Michaelson MD, McDermott DF, Cella D, Wagner LI, Haas NB, Carducci MA, Harshman LC, Allaf ME. The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER? Future Oncol. 2019 May; 15(15):1683-1695.
-
Crona DJ, Skol AD, Leppänen VM, Glubb DM, Etheridge AS, Hilliard E, Peña CE, Peterson YK, Klauber-DeMore N, Alitalo KK, Innocenti F. Genetic Variants of VEGFA and FLT4 Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with Sorafenib. Cancer Res. 2019 01 01; 79(1):231-241.
-
Jester R, Znoyko I, Garnovskaya M, Rozier JN, Kegl R, Patel S, Tran T, Abedalthagafi M, Horbinski CM, Richardson M, Wolff DJ, Lapadat R, Moore W, Rodriguez FJ, Mull J, Olar A. Expression of renal cell markers and detection of 3p loss links endolymphatic sac tumor to renal cell carcinoma and warrants careful evaluation to avoid diagnostic pitfalls. Acta Neuropathol Commun. 2018 10 19; 6(1):107.
-
Barata PC, Mendiratta P, Kotecha R, Gopalakrishnan D, Juloori A, Chao ST, Koshkin V, Ornstein M, Gilligan TD, Wood LS, Rini BI, Angelov L, Garcia JA. Effect of Switching Systemic Treatment After Stereotactic Radiosurgery for Oligoprogressive, Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer. 2018 10; 16(5):413-419.e1.
-
Parilla M, Kadri S, Patil SA, Ritterhouse L, Segal J, Henriksen KJ, Antic T. Are Sporadic Eosinophilic Solid and Cystic Renal Cell Carcinomas Characterized by Somatic Tuberous Sclerosis Gene Mutations? Am J Surg Pathol. 2018 07; 42(7):911-917.
-
Pal SK, Bergerot P, Dizman N, Bergerot C, Adashek J, Madison R, Chung JH, Ali SM, Jones JO, Salgia R. Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma. Eur Urol. 2018 07; 74(1):124-128.
-
McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, Gore ME, Ravaud A, Bracarda S, Suárez C, Danielli R, Gruenwald V, Choueiri TK, Nickles D, Jhunjhunwala S, Piault-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. 2018 06; 24(6):749-757.
-
Yu X, Liu F, Zeng L, He F, Zhang R, Yan S, Zeng Z, Shu Y, Zhao C, Wu X, Lei J, Zhang W, Yang C, Wu K, Wu Y, An L, Huang S, Ji X, Gong C, Yuan C, Zhang L, Feng Y, Huang B, Liu W, Zhang B, Dai Z, Wang X, Liu B, Haydon RC, Luu HH, Gan H, He TC, Chen L. Niclosamide Exhibits Potent Anticancer Activity and Synergizes with Sorafenib in Human Renal Cell Cancer Cells. Cell Physiol Biochem. 2018; 47(3):957-971.
-
Tretiakova M, Mehta V, Kocherginsky M, Minor A, Shen SS, Sirintrapun SJ, Yao JL, Alvarado-Cabrero I, Antic T, Eggener SE, Picken MM, Paner GP. Predominantly cystic clear cell renal cell carcinoma and multilocular cystic renal neoplasm of low malignant potential form a low-grade spectrum. Virchows Arch. 2018 Jul; 473(1):85-93.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|